Cargando…

Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment – a health economic analysis using German DRG data

Complicated infections such as osteomyelitis, skin and soft tissue infections or endocarditis often require antibiotic therapies that can last up to several weeks. The prolonged hospital length of stay (LOS) leads to a dramatic increase in costs. Single-dose intravenous Dalbavancin is a novel antimi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilke, Michael, Worf, Kerstin, Preisendörfer, Birgit, Heinlein, Wolfgang, Kast, Tilman, Bodmann, Klaus-Friedrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	German Medical Science GMS Publishing House 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839362/ https://www.ncbi.nlm.nih.gov/pubmed/31728264 http://dx.doi.org/10.3205/id000043

Ejemplares similares

Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON study
por: Wilke, Michael, et al.
Publicado: (2020)

The use of a standardized PCT-algorithm reduces costs in intensive care in septic patients - a DRG-based simulation model
por: Wilke, MH, et al.
Publicado: (2011)

Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapy
por: Wilke, MH, et al.
Publicado: (2011)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

Pharmaco-economic evaluation of antibiotic therapy strategies in DRG-based healthcare systems - a new approach
por: Wilke, MH, et al.
Publicado: (2010)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
por: Knafl, D., et al.
Publicado: (2016)

Transition of Care with Dalbavancin: a Successful Cost-Saving Stewardship Program through Decreased Length of Stay
por: Terriff, Colleen
Publicado: (2017)

Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Lueking, Richard, et al.
Publicado: (2022)

Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals
por: Béraud, Guillaume, et al.
Publicado: (2021)

1385. Pathway with single-dose long-acting intravenous antibiotic dalbavancin is a cost-saving alternative to usual inpatient care of acute bacterial skin and skin structure infections (ABSSSI)
por: Lovecchio, Frank, et al.
Publicado: (2022)

Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report
por: GUZEK, Aneta, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

108. Evaluation of the Impact of Dalbavancin Usage on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Wei, Wenjing, et al.
Publicado: (2021)

A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice
por: Hanses, Frank, et al.
Publicado: (2022)

The continuous downgrading of malnutrition in the German DRG system: possible effects on the treatment of patients at risk for malnutrition
por: Stollhof, Laura E., et al.
Publicado: (2019)

Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections
por: Sivori, Francesca, et al.
Publicado: (2022)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Calculated parenteral initial treatment of bacterial infections: Introduction and antibiotics
por: Bodmann, Klaus-Friedrich, et al.
Publicado: (2020)

Carbapenem-resistant gram-negative bacteria in Germany: incidence and distribution among specific infections and mortality: an epidemiological analysis using real-world data
por: Wilke, Michael H., et al.
Publicado: (2022)

Prevalence and molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) among pigs on German farms and import of livestock-related MRSA into hospitals
por: Köck, R., et al.
Publicado: (2009)

The data collection process established for the German DRG system over the last six years with focus on data quality
por: Rusert, Mathias
Publicado: (2008)

MRSA in a large German University Hospital: Male gender is a significant risk factor for MRSA acquisition
por: Kupfer, Markus, et al.
Publicado: (2010)

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects
por: Scoble, Patrick J., et al.
Publicado: (2015)

P046: Validation of a simple tool to save resources with previous MRSA carriers
por: Agostinho, A, et al.
Publicado: (2013)

Intravenous Administration of Triptonide Attenuates CFA-Induced Pain Hypersensitivity by Inhibiting DRG AKT Signaling Pathway in Mice
por: Ling, Yue-Juan, et al.
Publicado: (2020)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2021)

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

Global trends of dalbavancin: A bibliometric analysis
por: Monteagudo‐Martínez, Nuria, et al.
Publicado: (2022)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

Fungicide-Saving Potential and Economic Advantages of Fungus-Resistant Grapevine Cultivars
por: Eisenmann, Birgit, et al.
Publicado: (2023)

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis
por: Jeck, Julia, et al.
Publicado: (2023)

A methodology for refining AR-DRG
por: Aisbett, CW
Publicado: (2011)

The usefulness of Enhanced Recovery After Surgery concepts for colorectal resections: an economic analysis under DRG conditions
por: Koch, Franziska, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q34a2pdap7rha6434c0llhqi1f